|Videos|April 13, 2017

Zika Virus: From Mother to Fetus

David A. Schwartz, MD, MS Hyg, FCAP, clinical professor of pathology at Medical College of Georgia, Augusta University, explains his research, which focuses on mechanisms of transmission of the Zika virus from mother to child.

David A. Schwartz, MD, MS Hyg, FCAP, clinical professor of pathology at Medical College of Georgia, Augusta University, explains his research, which focuses on mechanisms of transmission of the Zika virus from mother to child.

Interview Transcript (slightly modified for readability)

“I, amongst several things that I do, am an obstetric and placental pathologist. I study the mechanisms of transmission of infections between pregnant women and the fetus, which is obviously a major problem, with not just Zika virus, but other emerging agents, such as Ebola virus, and some others.

I helped design studies that look at how [Zika] may be transmitted from a pregnant woman to her unborn child. As part of that I look at placentas, which, of course, [is] the baby’s largest organ. I sometimes look at maternal factors, and as an epidemiologist I’m also looking at behavioral risk factors, as well, and even some basic scientific issues, such as virology issues, and things like that.

Certainly, we’re at the very preliminary stages of this. We’ve only known that the Zika virus definitively is responsible for these fetal malformations since last year. There’s been very rapid progress. I’ve been doing this work for over 30 years and I’ve never seen such rapid progress on an emerging infection as I’ve seen with Zika virus.

Myself, in terms of what I’m finding, is that the Zika virus, interestingly enough, seems to go through the placenta and cause very little abnormality of pathology. And that’s very different than what we see with most other infections that are transmitted from pregnant women to their fetuses.

I’ve given a talk on that [at the First International Conference on Zika virus], and the findings are very technical, but a summary of that would be that this virus is able to cross the placenta, we believe, causing very little, if no inflammation at all, which is very unusual for a trans-placental infection.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.